Figure S4 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Shu-Xiong Zeng,Yanjun Zhu,Ai-Hong Ma,Weimin Yu,Hongyong Zhang,Tzu-Yin Lin,Wei Shi,Clifford G. Tepper,Paul T. Henderson,Susan Airhart,Jian-Ming Guo,Chuan-Liang Xu,Ralph W. deVere White,Chong-Xian Pan

DOI: https://doi.org/10.1158/1078-0432.22468512

2023-01-01

Abstract:Ki67 and cleaved caspase 3 expression in BL0440 tumors

What problem does this paper attempt to address?

Figure S5 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Shu-Xiong Zeng,Yanjun Zhu,Ai-Hong Ma,Weimin Yu,Hongyong Zhang,Tzu-Yin Lin,Wei Shi,Clifford G. Tepper,Paul T. Henderson,Susan Airhart,Jian-Ming Guo,Chuan-Liang Xu,Ralph W. deVere White,Chong-Xian Pan

DOI: https://doi.org/10.1158/1078-0432.22468509

2023-01-01

Abstract:p-p70S6K, pS6 and p-ERK expression in bladder cancer cells treated with pictilisib
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

Margaret A. Knowles,Fiona M. Platt,Rebecca L. Ross,Carolyn D. Hurst

DOI: https://doi.org/10.1007/s10555-009-9198-3

2009-12-01

Cancer and Metastasis Reviews

Abstract:The phosphatidylinositol 3-kinase (PI3K) pathway is a critical signal transduction pathway that regulates multiple cellular functions. Aberrant activation of this pathway has been identified in a wide range of cancers. Several pathway components including AKT, PI3K and mTOR represent potential therapeutic targets and many small molecule inhibitors are in development or early clinical trials. The complex regulation of the pathway, together with the multiple mechanisms by which it can be activated, make this a highly challenging pathway to target. For successful inhibition, detailed molecular information on individual tumours will be required and it is already clear that different tumour types show distinct combinations of alterations. Recent results have identified alterations in pathway components PIK3CA, PTEN, AKT1 and TSC1 in bladder cancer, some of which are significantly related to tumour phenotype and clinical behaviour. Co-existence of alterations to several PI3K pathway genes in some bladder tumours indicates that these proteins may have functions that are not related solely to the known canonical pathway.

oncology
The Predictive Value of PFKFB3 in Bladder Cancer Prognosis

Dongxu Qiu,Bin Zhao,Wenda Wang,Guoyang Zheng,Zhan Wang,Xu Wang,Yanan Li,Zhangcheng Liao,Yang Zhao,Yushi Zhang

DOI: https://doi.org/10.1016/j.heliyon.2024.e31347

IF: 3.776

2024-01-01

Heliyon

Abstract:6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3 (PFKFB3) influences cancer progression via participating in tumor aerobic glycolysis. In this study, we aimed to evaluate the prognostic significance of PFKFB3 in bladder cancer (BLCA) patients by analyzing a combination of publicly available databases, clinical patient data, and bladder tumor samples from our hospital. Single-cell and bulk RNA-seq data of bladder cancer, obtained from ENA, GEO, and TCGA databases, were utilized for our analysis. The results indicated that PFKFB3 mRNA expression was markedly elevated in bladder cancer compared to paired normal tissue. Furthermore, BLCA patients with high PFKFB3 expression exhibited a significantly worse prognosis (P<0.05). To validate these findings, clinical data and immunohistochemistry staining were performed on specimens obtained from 89 BLCA patients who underwent radical cystectomy at either Qingdao University Affiliated Hospital or Peking Union Medical College Hospital. The findings from this verification process confirmed that high expression of PFKFB3 serves as a biomarker for predicting worse prognosis in BLCA patients (OR: 2.462, 95% CI: 1.202-5.042, P = 0.012). To facilitate clinical application, we developed a nomogram based on four variables, including PFKFB3 expression, to predict the survival of BLCA patients. Importantly, this nomogram demonstrated a low mean prediction error of 0.03. Taken together, our findings suggest that PFKFB3 has the potential to serve as both a prognostic biomarker and a therapeutic target for BLCA patients.
Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth

Weidong Peng,Haojie Zhang,Mingwei Yin,Dejie Kong,Liping Kang,Xinkun Teng,Jingjing Wang,Zhimin Chu,Yating Sun,Pengpeng Long,Chengying Cui,Bin Lyu,Jinzhi Zhang,Han Xiao,Mingqing Wu,Yongqiang Wang,Yang Li

DOI: https://doi.org/10.1038/s41389-024-00529-y

2024-07-27

Oncogenesis

Abstract:Bladder cancer is characterized by aberrant activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling, underscoring the significance of directing therapeutic efforts toward the PI3K pathway as a promising strategy. In this study, we discovered that PI3K serves as a potent therapeutic target for bladder cancer through a high-throughput screening of inhibitory molecules. The PI3K inhibitor demonstrated a robust anti-tumor efficacy, validated both in vitro and in vivo settings. Nevertheless, the feedback activation of JAK1-STAT3 signaling reinstated cell and organoid survival, leading to resistance against the PI3K inhibitor. Mechanistically, the PI3K inhibitor suppresses PTPN11 expression, a negative regulator of the JAK-STAT pathway, thereby activating STAT3. Conversely, restoration of PTPN11 enhances the sensitivity of cancer cells to the PI3K inhibitor. Simultaneous inhibition of both PI3K and STAT3 with small-molecule inhibitors resulted in sustained tumor regression in patient-derived bladder cancer xenografts. These findings advocate for a combinational therapeutic approach targeting both PI3K and STAT3 pathways to achieve enduring cancer eradication in vitro and in vivo, underscoring their promising therapeutic efficacy for treating bladder cancer.
Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Qi Zhou,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yan Zhu,Yi Shen,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418973.v1

2023-01-01

Abstract:The associations among the expression of PD-L1, ITGB6, STAT3 and p-STAT3 and survival of Bladder Urothelial Cancer Patients
Identification of key candidate genes and biological pathways in bladder cancer

Xin Gao,Yinyi Chen,Mei Chen,Shunlan Wang,Xiaohong Wen,Shufang Zhang

DOI: https://doi.org/10.7717/peerj.6036

IF: 3.061

2018-12-04

PeerJ

Abstract:Background Bladder cancer is a malignant tumor in the urinary system with high mortality and recurrence rates. However, the causes and recurrence mechanism of bladder cancer are not fully understood. In this study, we used integrated bioinformatics to screen for key genes associated with the development of bladder cancer and reveal their potential molecular mechanisms. Methods The GSE7476 , GSE13507 , GSE37815 and GSE65635 expression profiles were downloaded from the Gene Expression Omnibus database, and these datasets contain 304 tissue samples, including 81 normal bladder tissue samples and 223 bladder cancer samples. The RobustRankAggreg (RRA) method was utilized to integrate and analyze the four datasets to obtain integrated differentially expressed genes (DEGs), and the gene ontology (GO) functional annotation and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis were performed. Protein-protein interaction (PPI) network and module analyses were performed using Cytoscape software. The OncoLnc online tool was utilized to analyze the relationship between the expression of hub genes and the prognosis of bladder cancer. Results In total, 343 DEGs, including 111 upregulated and 232 downregulated genes, were identified from the four datasets. GO analysis showed that the upregulated genes were mainly involved in mitotic nuclear division, the spindle and protein binding. The downregulated genes were mainly involved in cell adhesion, extracellular exosomes and calcium ion binding. The top five enriched pathways obtained in the KEGG pathway analysis were focal adhesion (FA), PI3K-Akt signaling pathway, proteoglycans in cancer, extracellular matrix (ECM)-receptor interaction and vascular smooth muscle contraction. The top 10 hub genes identified from the PPI network were vascular endothelial growth factor A (VEGFA), TOP2A, CCNB1, Cell division cycle 20 (CDC20), aurora kinase B, ACTA2, Aurora kinase A, UBE2C, CEP55 and CCNB2. Survival analysis revealed that the expression levels of ACTA2, CCNB1, CDC20 and VEGFA were related to the prognosis of patients with bladder cancer. In addition, a KEGG pathway analysis of the top 2 modules identified from the PPI network revealed that Module 1 mainly involved the cell cycle and oocyte meiosis, while the analysis in Module 2 mainly involved the complement and coagulation cascades, vascular smooth muscle contraction and FA. Conclusions This study identified key genes and pathways in bladder cancer, which will improve our understanding of the molecular mechanisms underlying the development and progression of bladder cancer. These key genes might be potential therapeutic targets and biomarkers for the treatment of bladder cancer.

multidisciplinary sciences
Figure S3 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418982

2023-01-01

Abstract:RORC Sensitizes Bladder Cancer Cells to Cisplatin
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer

Shaoming Zhu,A-Hong Ma,Zheng Zhu,Elio Adib,Ting Rao,Na Li,Kaiyuan Ni,Veera Chandra Sekhar Reddy Chittepu,Rao Prabhala,Juan Garisto Risco,David Kwiatkowski,Kent Mouw,Guru Sonpavde,Fan Cheng,Chong-xian Pan

DOI: https://doi.org/10.1136/jitc-2021-002917

IF: 12.469

2021-11-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Immune checkpoint blockade (ICB) induces durable response in approximately 20% of patients with advanced bladder urothelial cancer (aUC). Over 50% of aUCs harbor genomic alterations along the phosphoinositide 3-kinase (PI3K) pathway. The goal of this project was to determine the synergistic effects and mechanisms of action of PI3K inhibition and ICB combination in aUC. Methods Alterations affecting the PI3K pathway were examined in The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map databases. Human and mouse cells with Pten deletion were used for in vitro studies. C57BL/6 mice carrying syngeneic tumors were used to determine in vivo activity, mechanisms of action and secondary resistance of pan-PI3K inhibition, ICB and combination. Results Alterations along the PI3K pathway occurred in 57% of aUCs in TCGA. CRISPR (clustered regularly interspaced short palindromic repeats) knockout of PIK3CA induced pronounced inhibition of cell proliferation (p=0.0046). PI3K inhibition suppressed cancer cell growth, migration and colony formation in vitro. Pan-PI3K inhibition, antiprogrammed death 1 (aPD1) therapy and combination improved the overall survival (OS) of syngeneic mice with PTEN-deleted tumors from 27 days of the control to 48, 37, and 65 days, respectively. In mice with tumors not containing a PI3K pathway alteration, OS was prolonged by the combination but not single treatments. Pan-PI3K inhibition significantly upregulated CD80, CD86, MHC-I, and MHC-II in dendritic cells, and downregulated the transforming growth factor beta pathway with a false discovery rate-adjusted q value of 0.001. Interferon alpha response was significantly upregulated with aPD1 therapy (q value: <0.001) and combination (q value: 0.027). Compared with the control, combination treatment increased CD8 + T-cell infiltration (p=0.005), decreased T reg -cell infiltration (p=0.036), and upregulated the expression of multiple immunostimulatory cytokines and granzyme B (p<0.01). Secondary resistance was associated with upregulation of the mammalian target of rapamycin (mTOR) pathway and multiple Sprr family genes. Conclusions The combination Pan-PI3K inhibition and ICB has significant antitumor effects in aUC with or without activated PI3K pathway and warrants further clinical investigation. This combination creates an immunostimulatory tumor milieu. Secondary resistance is associated with upregulation of the mTOR pathway and Sprr family genes.

oncology,immunology
Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway

V Sgnaolin,T C B Pereira,M R Bogo,R Zanin,A M O Battastini,F B Morrone,M M Campos

DOI: https://doi.org/10.1007/s10637-012-9907-6

Abstract:Kinins and their receptors have been recently implicated in cancer. Using functional and molecular approaches, we investigated the relevance of kinin B1 and B2 receptors in bladder cancer. Functional studies were conducted using bladder cancer cell lines, and human biopsies were employed for molecular studies. Both B1 des-Arg(9)-BK and B2 BK receptor agonists stimulated the proliferation of grade 3-derived T24 bladder cancer cells. Furthermore, treatment with B1 and B2 receptor antagonists (SSR240612 and HOE140) markedly inhibited the proliferation of T24 cells. Only higher concentrations of BK increased the proliferation of the grade 1 bladder cancer cell line RT4, while des-Arg(9)-BK completely failed to induce its proliferation. Real-time PCR revealed that the mRNA expression of kinin receptors, particularly B1 receptors, was increased in T24 cells relative to RT4 cells. Data from bladder cancer human biopsies revealed that B1 receptor expression was increased in all tumor samples and under conditions of chronic inflammation. We also show novel evidence demonstrating that the pharmacological inhibition of PI3Kγ (phosphatidylinositol 3-kinase) with AS252424, concentration-dependently reduced T24 cell proliferation induced by BK or des-Arg(9)-BK. Finally, the incubation of T24 cells with kinin agonists led to a marked activation of the PI3K/AKT and ERK 1/2 signaling pathways, whereas p38 MAP kinase remained unaffected. Kinin receptors, especially B1 receptors, appear to be implicated in bladder cancer progression. It is tempting to suggest that selective kinin antagonists might represent potential alternative therapies for bladder cancer.
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer

Lisi Zheng,Jingxuan Wang,Shan Han,Li Zhong,Zefu Liu,Bin Li,Ruhua Zhang,Liwen Zhou,Xianchong Zheng,Zhenhua Liu,Cuiling Zeng,Ruonan Li,Yezi Zou,Liqin Wang,Yuanzhong Wu,Tiebang Kang

DOI: https://doi.org/10.1186/s13046-024-03224-3

IF: 12.658

2024-11-27

Journal of Experimental & Clinical Cancer Research

Abstract:Bladder cancer (BLCA) is a common malignancy characterized by dysregulated transcription and a lack of effective therapeutic targets. In this study, we aimed to identify and evaluate novel targets with clinical potential essential for tumor growth in BLCA.

oncology
Therapeutic Targets and Predictive Markers of Treatment Efficacy of Bladder Cancer

Mengran Shi,Luyao Wang,Zhao Yang,Chong Li

DOI: https://doi.org/10.18063/cp.v2i2.275

2020-01-01

Abstract:Bladder cancer (BC) is one of the most common types of cancers in the world. Despite various treatments are currently in place, the prognosis of BC does not seem to improve. Therefore, this prompts us to search for alternative treatments. The understanding of the molecular changes in cancer offers the prospect of targeting the key elements responsible for cancer development and progression, and thus, helps to develop a more effective and robust targeted therapy that does not endanger normal cells. At present, protein-based therapeutic targets such as programmed death ligand 1, epidermal growth factor receptor and aberrantly glycosylated integrin-α3β1, and genetic targets such as p53, human EGF receptor-2, and miR-23b are promising targets for BC treatment. In addition, predictive markers of treatment efficacy for BC, such as meiotic recombination 11, excision repair cross-complementing group 1, and multidrug resistance 1 gene are essential in facilitating clinicians to design and implement suitable and effective therapies for BC patients. This review discusses the pivotal role of these markers in the development of targeted therapy and the estimation of the clinical outcome of BC.
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer

Xiting Huang,Qian Wang,Yanyang Nan,Xuyao Zhang,Ke Xu,Dianwen Ju,Weihong Ding

DOI: https://doi.org/10.3390/biomedicines12092152

IF: 4.757

2024-09-23

Biomedicines

Abstract:Background: Although immunotherapy has shown potential in cancer treatment, current immunotherapeutics for bladder cancer are limited by a low response rate. Therefore, it is necessary to investigate other suitable immunotherapeutic targets and strategies for bladder cancer. Methods: To evaluate whether CD47 could be a suitable target for bladder cancer immunotherapy, CD47 protein expression levels in 116 bladder cancer tissue samples were assessed by IHC staining. In vitro anti-tumor effect of blocking CD47 was examined by phagocytosis assays. In vivo anti-tumor effects of targeting CD47 and angiogenesis were experimented in the HSPCs-CDX model. Results: We find that CD47 is highly expressed in bladder cancer samples and is associated with poor prognosis. Blocking CD47 could enhance the human PBMC-derived macrophages' phagocytosis of T24 (from 10.40% to 29.70%) and 5637 (from 5.31% to 33.52%) human bladder cancer cells, as well as demonstrate anti-tumor effects in the HSPCs-CDX model (tumor growth inhibition rate, TGI: 33.05%). During CD47 treatment, we observed that the level of angiogenesis increased after CD47 blockade, and it might undermine the effect of CD47 immunotherapy. We then combined CD47 blockade with anti-angiogenic drugs to treat bladder cancer and discovered that inhibiting angiogenesis could further improve the anti-tumor effect of CD47 blockade (TGI: 76.39%). Finally, we tested the anti-tumor effect of co-targeting CD47 and angiogenesis using a bispecific fusion protein, SIRPα-VEGFR1, which successfully inhibited tumor growth to a similar extent as a combination therapy. Conclusions: Our study suggests that targeting CD47 could inhibit the growth of bladder cancer by promoting macrophage-mediated anti-tumor immunity. Moreover, blocking CD47 and angiogenesis could achieve a potent anti-tumor effect and could be an effective immunotherapy strategy for bladder cancer.
Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data

Yingkun Xu,Guangzhen Wu,Jianyi Li,Jiatong Li,Ningke Ruan,Liye Ma,Xiaoyang Han,Yanjun Wei,Liang Li,Hongge Zhang,Yougen Chen,Qinghua Xia

DOI: https://doi.org/10.1155/2020/8283401

2020-01-23

Abstract:Bladder cancer (BLCA) is a common malignant cancer, and it is the most common genitourinary cancer in the world. The recurrence rate is the highest of all cancers, and the treatment of BLCA has only slightly improved over the past 30 years. Genetic and environmental factors play an important role in the development and progression of BLCA. However, the mechanism of cancer development remains to be proven. Therefore, the identification of potential oncogenes is urgent for developing new therapeutic directions and designing novel biomarkers for the diagnosis and prognosis of BLCA. Based on this need, we screened overlapping differentially expressed genes (DEG) from the GSE7476, GSE13507, and TCGA BLCA datasets. To identify the central genes from these DEGs, we performed a protein-protein interaction network analysis. To investigate the role of DEGs and the underlying mechanisms in BLCA, we performed Gene Ontology (GO) and Kyoto Gene and Genomic Encyclopedia (KEGG) analysis; we identified the hub genes via different evaluation methods in cytoHubba and then selected the target genes by performing survival analysis. Finally, the relationship between these target genes and tumour immunity was analysed to explore the roles of these genes. In summary, our current studies indicate that both cell division cycle 20 (CDC20) and abnormal spindle microtubule assembly (ASPM) genes are potential prognostic biomarkers for BLCA. It may also be a potential immunotherapeutic target with future clinical significance.
Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418979

2023-01-01

Abstract:PD-L1 Attenuates Anti-tumor effect of RORC in Bladder cancer
Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Yongkang Zou,Zhi Qi,Weilong Guo,Liuzhen Zhang,Marcus Ruscetti,Tanu Shenoy,Ningshu Liu,Hong Wu

DOI: https://doi.org/10.1158/1535-7163.22504362

2023-01-01

Abstract:Figure S1. Effects of BAY1082439 on cell apoptosis and cell cycle; Figure S2. BAY1082439 is well tolerated in vivo; Figure S3. BAY1082439 treatment impedes prostate tumor invasion; Figure S4. BAY1082439 treatment inhibit CRPC growth in castrated CP mice; Figure S5. B cell infiltration promote CRPC growth in CP model; Figure S6. Effects of BAY1082439 on splenic B cell growth and tumor infiltrating CD8 T cell
Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB

Situ Xiong,Sheng Li,Jin Zeng,Jianqiang Nie,Taobin Liu,Xiaoqiang Liu,Luyao Chen,Bin Fu,Jun Deng,Songhui Xu

DOI: https://doi.org/10.3389/fimmu.2023.1253586

IF: 7.3

2023-09-19

Frontiers in Immunology

Abstract:Objectives: To identify the molecular subtypes and develop a scoring system for the tumor immune microenvironment (TIME) and prognostic features of bladder cancer (BLCA) based on the platinum-resistance-related (PRR) genes analysis while identifying P4HB as a potential therapeutic target. Methods: In this study, we analyzed gene expression data and clinical information of 594 BLCA samples. We used unsupervised clustering to identify molecular subtypes based on the expression levels of PRR genes. Functional and pathway enrichment analyses were performed to understand the biological activities of these subtypes. We also assessed the TIME and developed a prognostic signature and scoring system. Moreover, we analyzed the efficacy of immune checkpoint inhibitors. Then we conducted real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) experiments to detect the expression level of prolyl 4-hydroxylase subunit beta (P4HB) in BLCA cell lines. Transfection of small interference ribonucleic acid (siRNA) was performed in 5637 and EJ cells to knock down P4HB, and the impact of P4HB on cellular functions was evaluated through wound-healing and transwell assays. Finally, siRNA transfection of P4HB was performed in the cisplatin-resistant T24 cell to assess its impact on the sensitivity of BLCA to platinum-based chemotherapy drugs. Results: In a cohort of 594 BLCA samples (TCGA-BLCA, n=406; GSE13507, n=188), 846 PRR-associated genes were identified by intersecting BLCA expression data from TCGA and GEO databases with the PRR genes from the HGSOC-Platinum database. Univariate Cox regression analysis revealed 264 PRR genes linked to BLCA prognosis. We identified three molecular subtypes (Cluster A-C) and the PRR scoring system based on PRR genes. Cluster C exhibited a better prognosis and lower immune cell infiltration compared to the other Clusters A and B. The high PRR score group was significantly associated with an immunosuppressive tumor microenvironment, poor clinical-pathological features, and a poor prognosis. Furthermore, the high PRR group showed higher expression of immune checkpoint molecules and a poorer response to immune checkpoint inhibitors than the low PRR group. The key PRR gene P4HB was highly expressed in BLCA cell lines, and cellular functional experiments in vitro indicate that P4HB may be an important factor influencing BLCA migration and invasion. Conclusion: Our study demonstrates that the PRR signatures are significantly associated with clinical-pathological features, the TIME, and prognostic features. The key PRR gene, P4HB, s a biomarker for the individualized treatment of BLCA patients.

immunology
An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived&nbsp;Mimetic Nanovesicles to Treat Bladder Cancer

Qidong Zhou,Weihong Ding,Zhiyu Qian,Quangang Zhu,Chuanyu Sun,Qin Yu,Zongguang Tai,Ke Xu

DOI: https://doi.org/10.21203/rs.3.rs-256327/v1

2021-01-01

Abstract:Abstract BackgroundThe tumor microenvironment in bladder cancer exerts an inhibitory effect on immune effector cells. Thus, removing this inhibitory effect could help improve the efficacy of immune checkpoint inhibitors, and combination immunotherapy is a promising strategy for increasing the proportion of patients with bladder cancer who benefit from immune checkpoint inhibitors. However, it is difficult to effectively and simultaneously deliver multiple drugs to the tumor tissue. In this study, we describe the design and in vivo validation of macrophage-derived exosome-mimetic nanovesicles (EMVs) as a nanoplatform for coloading and targeted delivery of a CD73 inhibitor (AB680) and monoclonal antibodies targeting programmed cell death ligand 1 (aPDL1). ResultsOur results indicated that these nanocomplexes (AB680@EMVs-aPDL1) were highly stable, provided adequate biosafety in vivo, and exhibited enhanced targeting in a mouse model of bladder cancer. Moreover, the CD73 inhibitor reduced extracellular adenosine production, and the combination therapy significantly promoted activation of cytotoxic T lymphocytes, resulting in suppression of tumor growth in vivo. ConclusionsTherefore, using EMVs to deliver a combination of aPDL1 and a CD73 inhibitor may be an effective combined immunotherapy strategy for treating bladder cancer.
Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling

Chun-Te Wu,Wei-Yu Lin,Wen-Cheng Chen,Miao-Fen Chen

DOI: https://doi.org/10.1245/s10434-018-6706-0

Abstract:Background: CD44, a cancer stem cell surface marker, is associated with treatment resistance and prognosis in some cancers. In the present study, we examined the predictive value of CD44 in muscle-invasive bladder cancer (MIBC). Methods: We retrospectively analyzed the clinical outcomes of 105 MIBC patients and correlated these outcomes with the expression of CD44. Furthermore, the bladder cancer cell lines HT1197 and MB49 were selected for cellular and animal experiments to investigate the correlation between CD44 and tumor aggressiveness. Results: Analysis of clinical specimens indicated that CD44 staining was significantly associated with a higher clinical stage, higher locoregional failure rate, and lower disease-specific survival rate for MIBC patients. Using cellular experiments and orthotopic tumor models, we showed that CD44+ bladder cancer cells had a higher invasion ability and augmented epithelial-mesenchymal transition (EMT) compared with CD44 cells. There was a significant correlation between interleukin (IL)-6 and CD44 levels noted by in vitro testing, and clinical samples. Blockade of IL-6 attenuated the expression of CD44, cancer stem-cell-like properties, and aggressive tumor behavior in vitro and in vivo. The related changes included the attenuated STAT3 activation and EMT, and decreased programmed death ligand 1-mediated T-cell suppression. Conclusion: Our findings suggest that CD44 expression is positively associated with tumor aggressiveness in bladder cancer, and activated IL-6 signaling provides a suitable microenvironment for the induction of CD44 expression.
Abstract 3161: Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies

Jim Jinn-Chyuan Sheu,Chung Chang,Bo-Chen Lin,Tritium Hwang

DOI: https://doi.org/10.1158/1538-7445.am2023-3161

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract We have previously developed a unique HD-MAC (high-dimensional analysis of molecular alterations in cancer) platform that enables us to define independent tumor biomarkers from a group of clinically-significant genes. Using this platform, 26 genes were identified as independent prognosis biomarkers whose overexpression determine shorter overall survivals in patients with bladder cancer. Through clinical association study (including tumor stage, lymph node invasion, angiogenesis, and metastasis), a gene signature containing 6 biomarkers was established which can be validated by two independent cohorts. Gene knock down effects on cancer cell survival further revealed PPT2 and PRPF19 as potential targets for target-based therapy. Correlation study between genetic dependencies and drug sensitivities across cell lines suggested several potent lead compounds which are likely to function through similar mechanisms of gene effect actions. Our study therefore provides newly defined prognostic biomarkers as well as the associated therapeutic strategies for possible clinical applications in patients with bladder cancer. Citation Format: Jim Jinn-Chyuan Sheu, Chung Chang, Bo-Chen Lin, Tritium Hwang. Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3161.

oncology
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer

Melissa L Fishel,Hanyu Xia,Jack McGeown,David W McIlwain,May Elbanna,Ariel A Craft,Hristos Z Kaimakliotis,George E Sandusky,Chi Zhang,Roberto Pili,Mark R Kelley,Travis J Jerde

DOI: https://doi.org/10.1158/1535-7163.MCT-18-1166

Abstract:Bladder cancer is the ninth most common cause of cancer-related deaths worldwide. Although cisplatin is used routinely in treating bladder cancer, refractory disease remains lethal for many patients. The recent addition of immunotherapy has improved patient outcomes; however, a large cohort of patients does not respond to these treatments. Therefore, identification of innovative molecular targets for bladder cancer is crucial. Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein involved in both DNA repair and activation of transcription factors through reduction-oxidation (redox) regulation. High APE1/Ref-1 expression is associated with shorter patient survival time in many cancer types. In this study, we found high APE1/Ref-1 expression in human bladder cancer tissue relative to benign urothelium. Inhibition of APE1/Ref-1 redox signaling using APE1/Ref-1-specific inhibitors attenuates bladder cancer cell proliferation in monolayer, in three-dimensional cultures, and in vivo. This inhibition corresponds with an increase in apoptosis and decreased transcriptional activity of NF-κB and STAT3, transcription factors known to be regulated by APE1/Ref-1, resulting in decreased expression of downstream effectors survivin and Cyclin D1 in vitro and in vivo. We also demonstrate that in vitro treatment of bladder cancer cells with APE1/Ref-1 redox inhibitors in combination with standard-of-care chemotherapy cisplatin is more effective than cisplatin alone at inhibiting cell proliferation. Collectively, our data demonstrate that APE1/Ref-1 is a viable drug target for the treatment of bladder cancer, provide a mechanism of APE1/Ref-1 action in bladder cancer cells, and support the use of novel redox-selective APE1/Ref-1 inhibitors in clinical studies. SIGNIFICANCE: This work identifies a critical mechanism for APE1/Ref-1 in bladder cancer growth and provides compelling preclinical data using selective redox activity inhibitors of APE1/Ref-1 in vitro and in vivo.

Figure S4 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Figure S5 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

The Predictive Value of PFKFB3 in Bladder Cancer Prognosis

Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth

Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Identification of key candidate genes and biological pathways in bladder cancer

Figure S3 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer

Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer

Therapeutic Targets and Predictive Markers of Treatment Efficacy of Bladder Cancer

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer

Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data

Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB

An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived&amp;nbsp;Mimetic Nanovesicles to Treat Bladder Cancer

Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling

Abstract 3161: Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies

Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer

An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer